Premium
Simultaneous administration of Ang(1‐7) or A‐779 does not affect the chronic hypertensive effects of AngII in normal rats
Author(s) -
Collister John P,
Nahey David B
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.606.14
Subject(s) - angiotensin ii , antagonist , medicine , blood pressure , renin–angiotensin system , endocrinology , receptor
Despite the well described actions of Ang(1‐7) and its potential role in opposing the actions of angiotensin II (AngII), there have been relatively few studies examining the role of Ang(1‐7) in a chronic setting. It is well established that Ang(1‐7) plays a protective role in preventing deleterious chronic effects of AngII in the heart, but little is known of its role in modulating the chronic hypertensive effects of AngII. The current study was designed to test the hypothesis that simultaneous administration of either Ang(1‐7) or its antagonist A779 would attenuate or exacerbate the chronic hypertensive effects of AngII, respectively. To test this hypothesis, Sprague‐Dawley rats were instrumented with venous catheters and radio telemetric pressure transducers and begun on a normal (0.4%) NaCl diet. Arterial pressure responses were measured in rats treated with AngII (10 ng/kg/min, n=9) and compared with those treated simultaneously with AngII and Ang(1‐7) (24 µg/kg/hr, n=8), or the Ang(1‐7) antagonist A‐779 (24 µg/kg/hr, n=7) for 8 days. Mean arterial pressure rose significantly and similarly in all 3 groups of rats, such that by day 8 of AngII infusion, pressures had risen approximately 25‐30 mmHg in all rats. These results do not support the hypothesis that the chronic hypertensive effects of AngII in normal rats are altered by co‐administration of either Ang(1‐7) or its antagonist, A‐779.